Skip to main content

Press releases | June 18, 2024

Fried Frank acted as counsel to BofA Securities as financial advisor to Silk Road Medical, Inc. (NASDAQ:SILK), a leading minimally invasive medical device company for carotid artery procedures, in its $1.26 billion sale to Boston Scientific Corporation (NYSE: BSX), a global medical technology company. The transaction is expected to close in the second half of 2024.

The Fried Frank team was led by partner Roy Tannenbaum.


This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm’s data policy page for further information.